MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

MiNK Therapeutics (NASDAQ: INKT) announced an abstract acceptance for presentation at the American Thoracic Society (ATS) 2026 International Conference in Orlando, May 15-20, 2026.

Rhea-AI Summary

MiNK Therapeutics (NASDAQ: INKT) announced an abstract acceptance for presentation at the American Thoracic Society (ATS) 2026 International Conference in Orlando, May 15-20, 2026. The abstract describes a combination of N-803 and investigational agenT-797 for unresolving Coccidioides immitis infection.

Presenter Terese Hammond, MD, will present Poster Board #103 in Session D107 on Wednesday, May 20, 2026, 11:00 AM–1:00 PM EDT. In line with ATS rules, no data or results are disclosed until the conference presentation.

Argus Apr 1 session

+0.38% close to close Open Argus

Details

News Market Reaction – INKT

On Apr 1, the day this news came out, INKT closed 0.38% above the previous close.

Data tracked by StockTitan Argus for the Apr 1 session.

Market Context

This announcement centers on acceptance of an agenT-797 abstract for ATS 2026, adding to recent scie...

Analysis

This announcement centers on acceptance of an agenT-797 abstract for ATS 2026, adding to recent scientific and clinical visibility for MiNK’s iNKT platform. In the past six months, the company has highlighted Phase 2 progress, non-dilutive funding of up to ~$1.1M, and collaborations in pediatric oncology. Investors may watch for data quality at the conference, subsequent trial updates, and any utilization of the up to $150,000,000 shelf and related ATM program.

Key Figures

Conference dates: May 15–20, 2026 Presentation date: May 20, 2026 Session time: 11:00 AM – 1:00 PM (EDT) +1 more

Conference dates

May 15–20, 2026

ATS 2026 International Conference schedule

Presentation date

May 20, 2026

Poster presentation date at ATS 2026

Session time

11:00 AM – 1:00 PM (EDT)

Scheduled window for agenT-797 poster

Poster board

#103

Poster board assignment for ATS presentation

Historical Context

5 past events · Latest: Mar 31

5 events

1. Mar 31

   Earnings & pipeline

   24h Move

   +0.1%

   Q4/FY25 results, cash update, and advancing Phase 2 ARDS and GVHD programs.

2. Mar 17

   Earnings date set

   24h Move

   +4.9%

   Announcement of earnings date plus iNKT platform expansion and collaboration plans.

3. Mar 10

   New collaboration

   24h Move

   +29.3%

   Strategic C-Further partnership on PRAME-targeted TCR-engineered iNKT therapy.

4. Mar 10

   Partner program launch

   24h Move

   +29.3%

   C-Further launches pediatric oncology programs including MiNK-partnered PRAME iNKT therapy.

5. Feb 03

   Conference data

   24h Move

   +2.2%

   Keystone data on allo-iNKT therapy in IPF supporting disease-modifying potential.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

allogeneic, invariant natural killer T, allo-iNKT, interleukin-15 superagonist, +2 more

6 terms

allogeneic medical

"a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T"

Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.

invariant natural killer T medical

"pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies"

Invariant natural killer T (iNKT) cells are a rare, specialized type of immune cell that recognize certain fat-based signals and respond very quickly, acting like a built-in smoke alarm that both raises the alarm and directs other immune cells. They matter to investors because therapies or diagnostics that harness or measure iNKT activity can change how cancers, infections, and autoimmune diseases are treated or monitored, making them a potential catalyst for drug development and biotech valuation.

allo-iNKT medical

"pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies"

A donor-derived immune cell therapy made from invariant natural killer T (iNKT) cells that can be manufactured ahead of time and given to many patients without using their own cells. Investors care because it represents an “off‑the‑shelf” approach to cell therapy—more like a mass-produced drug than a one-off custom treatment—which can lower manufacturing costs, speed distribution, and scale revenue if safety and effectiveness are proven, while still facing regulatory and commercialization risks.

interleukin-15 superagonist medical

"Novel Interleukin-15 Superagonist (N-803) and Invariant Natural Killer T Cell"

A drug engineered to act like and amplify a natural immune signaling protein called interleukin-15, designed to strongly activate immune cells that can hunt cancer or infected cells. Investors care because these agents can drive major changes in a biotech’s clinical trial outcomes, regulatory approval chances, and commercial potential—think of it as adding a high-performance engine to an immune system vehicle, with higher reward but also higher development risk.

immunotherapy medical

"Combination Immunotherapy for Unresolving Coccidioides immitis Infection"

Treatment that uses or enhances the body’s immune system to detect and fight disease, most often cancers or chronic infections; think of it as training or arming the body’s own soldiers to find and destroy targets. It matters to investors because successful immunotherapies can lead to high-value drug approvals, recurring revenue from long-term treatments, and changes in competitive dynamics, while failures or safety issues in clinical trials can materially affect company valuations.

coccidioides immitis medical

"Combination Immunotherapy for Unresolving Coccidioides immitis Infection"

Coccidioides immitis is a soil‑dwelling fungus that can cause coccidioidomycosis, a respiratory infection spread by inhaling microscopic spores; think of it like dust that can sometimes carry a harmful mold. It matters to investors because outbreaks can affect healthcare demand, trigger regulatory or workplace safety costs, influence travel and agriculture in affected regions, and create liability or product‑supply impacts for companies operating where the fungus is common.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the ATS International Conference 2026 occurring May 15-20, 2026 in Orlando, Florida.

The abstract, titled “Novel Interleukin-15 Superagonist (N-803) and Invariant Natural Killer T Cell (agenT-797) Combination Immunotherapy for Unresolving Coccidioides immitis Infection,” highlights a novel combination approach leveraging immune activation and restoration in severe and persistent infections.

Presentation Details

• Presenter: Terese Hammond, MD
• Poster Board: #103
• Session Title: D107- Zebras of the Lung: Rare Infections, Immune Extremes, and Diagnostic Plot Twists
• Date/Time: Wednesday, May 20, 2026 | 11:00 AM – 1:00 PM (EDT)

In accordance with American Thoracic Society guidelines, no data or results are being disclosed at this time. Full details will be presented at the conference.

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK’s proprietary platform is designed to restore immune balance and drive cytotoxic responses across cancer, immune-mediated diseases, and pulmonary immune failure. MiNK’s lead candidate, agenT-797, is an off-the-shelf iNKT cell therapy currently in clinical development for GvHD, solid tumors, and severe pulmonary inflammation. With a scalable cryopreserved manufacturing process and differentiated biology bridging innate and adaptive immunity, MiNK is committed to developing next-generation immune reconstitution therapies. For more information, visit www.minktherapeutics.com or follow us on X @MiNK_iNKT.

About AgenT-797

AgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy that harnesses the dual power of innate and adaptive immunity. iNKTs function as “master regulators,” combining the cytotoxic capabilities of NK cells with T-cell–like antigen recognition and memory. This unique biology enables a robust, pathogen-agnostic immune response that can be directed against hard-to-treat tumors. Manufactured by MiNK Therapeutics in Lexington, MA, agenT-797 is a scalable, off-the-shelf product designed to provide accessible, transformative treatment options. In clinical trials, agenT-797 can bolster peripheral memory T-cell activation, enhance tumor infiltration, and potentially improve outcomes for patients with solid cancers (Cytryn et al. AACR IO 2024, Oncogene. 2024) and to combat inflammation in critically ill patients with severe respiratory pathology (Nature Communications. 2024).

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, safety, and anticipated benefits of agenT-797; clinical trial design, timing, and enrollment; and MiNK’s broader development plans. These statements are subject to risks and uncertainties detailed in MiNK’s most recent filings with the Securities and Exchange Commission. MiNK cautions investors not to place undue reliance on these statements, which speak only as of the date of this release.

Contacts:

Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com

Source: MiNK Therapeutics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will MiNK Therapeutics (INKT) present at the ATS 2026 conference on May 20, 2026?

MiNK will present an abstract on a combination immunotherapy of N-803 and agenT-797 for persistent Coccidioides infection. According to the company, the poster (Board #103) is scheduled in Session D107 on May 20, 2026, 11:00 AM–1:00 PM EDT.

Who is the presenter for MiNK Therapeutics' (INKT) poster at ATS 2026 and where is it located?

The presenter is Terese Hammond, MD, presenting Poster Board #103. According to the company, the poster is part of Session D107: Zebras of the Lung, on May 20, 2026, between 11:00 AM and 1:00 PM EDT in Orlando.

What is the title of MiNK Therapeutics' (INKT) ATS 2026 abstract and what does it describe?

The abstract is titled ‘Novel Interleukin-15 Superagonist (N-803) and Invariant Natural Killer T Cell (agenT-797) Combination Immunotherapy for Unresolving Coccidioides immitis Infection.’ According to the company, it highlights a combination approach using immune activation and restoration.

Will MiNK Therapeutics (INKT) disclose data from the agenT-797 ATS 2026 poster before the presentation?

No, MiNK will not disclose data or results prior to the conference presentation. According to the company, this follows American Thoracic Society guidelines and full details will be presented at the ATS session.

How can investors attend or view MiNK Therapeutics' (INKT) ATS 2026 presentation on agenT-797?

Investors can attend the poster session in person at ATS 2026 during the scheduled poster hours on May 20, 2026. According to the company, full presentation details and any post-conference materials will be available after the session.